Insitro is a machine learning-driven drug discovery company headquartered in San Francisco, California, that combines artificial intelligence with human genetics and high-throughput experimentation to develop new therapeutics for severe diseases, including neurodegenerative disorders. Founded in 2018 by Daphne Koller (former Professor at Stanford University and pioneer in machine learning and computational biology), Insitro has raised over $500M in funding and established strategic partnerships with major pharmaceutical companies. The company's approach leverages genetic data to identify validated drug targets and uses machine learning to predict drug response, accelerating the traditionally slow and expensive drug discovery process.
| Attribute |
Details |
| Headquarters |
San Francisco, CA, USA |
| Founded |
2018 |
| Co-Founders |
Daphne Koller, Ana O'Keefe, David Becks |
| CEO |
Daphne Koller |
| Funding |
$500M+ (Series C) |
| Employees |
~100+ |
| Investors |
Andreessen Horowitz, Google Ventures, SoftBank, resistance Capital |
¶ History and Milestones
| Year |
Milestone |
| 2018 |
Founded by Daphne Koller |
| 2019 |
First Series A ($30M) |
| 2020 |
Series B ($143M) |
| 2022 |
Series C ($400M) — one of largest for AI biotech |
| 2023 |
Partnership with Genentech for ALS |
| 2024 |
Advanced neuroscience programs into discovery |
Insitro's platform integrates multiple cutting-edge technologies:
- Machine Learning: Deep learning models trained on large-scale genomic and phenotypic data
- Human Genetics: Using genetic data to identify validated drug targets (genetic validation)
- In Silico Modeling: Computational approaches to predict drug response
- Stem Cell Models: Patient-derived cell lines for disease modeling
- High-Throughput Experimentation: Automated labs generating training data
What makes Insitro different from traditional drug discovery:
- Genetic validation first: Only pursue targets with human genetic evidence
- Machine learning integration: Predict efficacy and safety computationally
- Patient-derived models: Use induced pluripotent stem cells (iPSCs) from patients
- Closed-loop learning: Experimental data feeds back into ML models
| Capability |
Description |
| Target identification |
ML identifies genetically validated targets |
| Compound screening |
High-throughput screening with ML analysis |
| Patient stratification |
Identify which patients respond to treatment |
| Clinical trial design |
Optimize trial design using predictive models |
Insitro has a strong focus on neurodegenerative diseases, recognizing that:
- Genetic approaches can identify novel targets
- ML can model complex disease biology
- Patient-derived models capture individual variability
| Program |
Target |
Stage |
Indication |
| ALS Program |
Multiple |
Research |
Amyotrophic lateral sclerosis |
| Alzheimer's Program |
TBA |
Discovery |
Alzheimer's disease |
| Parkinson's Program |
TBA |
Discovery |
Parkinson's disease |
| CNS Platform |
Various |
Discovery |
Multiple neurodegenerative |
Insitro's ALS program represents a key focus area:
- Partnership with Genentech (2023)
- Uses patient-derived stem cell models
- Targets multiple mechanisms
- ML-driven target identification
- Oncology: Partnership with Bristol Myers Squibb
- Rare genetic diseases: Unmet needs with clear genetics
- Metabolic disorders: Metabolic conditions with genetic components
¶ Partnerships and Collaborations
- Announced: 2023
- Scope: Collaboration in ALS and neuroscience
- Focus: Joint drug discovery using Insitro's platform
- Value: Significant upfront and milestones
- Scope: Oncology partnership
- Focus: ML-driven cancer drug discovery
- Scope: Research collaboration
- Focus: Platform access and target validation
¶ Leadership and Team
- Daphne Koller: Co-founder and CEO —Former Professor at Stanford, pioneer in ML and computational biology, co-author of foundational work on conditional random fields and deep learning applications in biomedicine
- Ana O'Keefe: Co-founder —Expert in computational biology
- David Becks: Co-founder —Drug development expertise
The team combines expertise in:
- Machine learning and AI
- Computational biology
- Drug development
- Experimental biology
- Clinical development
¶ Funding and Financials
| Round |
Year |
Amount |
Lead Investors |
| Series A |
2019 |
$30M |
Andreessen Horowitz |
| Series B |
2020 |
$143M |
Andreessen Horowitz, GV |
| Series C |
2022 |
$400M |
Andreessen Horowitz, GV, SoftBank |
Total raised: $500M+
¶ Competitive Landscape
Insitro competes in the AI drug discovery space:
| Company |
Focus |
Distinction |
| Recursion |
AI + biology |
Automated experiments |
| Exscientia |
AI molecular design |
Generative AI |
| Relay Therapeutics |
Computational + experimental |
Allosteric modulation |
| Healx |
AI for rare disease |
Patient-centric |
- Strong academic foundation (Stanford AI lab heritage)
- Human genetics focus (genetic validation)
- Patient-derived models
- Major pharma partnerships validate approach
¶ Science and Publications
Insitro's approach is grounded in published science:
- Machine learning for drug discovery
- Stem cell models for neurodegenerative disease
- Genetic target validation methods
- Patient stratification approaches
Insitro's approach to Alzheimer's disease:
- Genetic risk factors inform target identification
- Patient-derived models capture disease biology
- ML can model complex multi-genic disease
- Focus on genetically validated targets
For Parkinson's disease:
- Identified genetic risk factors (LRRK2, GBA, etc.)
- Patient iPSC models for drug testing
- Focus on disease-modifying mechanisms
Strong focus with Genentech partnership:
- Multiple genetic forms (SOD1, C9orf72, FUS)
- Patient-derived motor neurons
- ML-driven target prioritization